BAKERSFIELD, Calif., Aug. 4, 2025 — MAVRK Capital Inc., the next-generation alternative asset manager at the intersection of agricultural credit lending and private equity, announced the first closing of their second fund targeting international produce growers.

The capital raise marks a key milestone for the entire MAVRK organization. With a goal to bring institutional-grade capital alongside multi-generational farming experience MAVRK is positioned to unlock attractive investments in one of the most underserved and essential sectors, perishable agriculture. The fund will directly purchase and finance produce-related receivables providing needed liquidity to growers, distributors, and retailers across the United States, Latin America and South America while continuing to connect world class growers with major U.S. retail purchasers.

“We are excited to announce this first Close of our second fund for our global lending,” said Jack Campbell, CEO of MAVRK Capital, Inc. “This investment will lead to the transformation of agriculture via institutional liquidity for growers allowing them to focus on building sustainable and predictive growing operations. We look forward to partnering with other institutional investors to build the future of agriculture.”

The investment was anchored by Valley Strong Ventures, alongside a number of family offices. MAVRK has also secured several hundred million in financing commitments, from leading financing providers, to facilitate further growth.

“Through Valley Strong Ventures, we are committed to driving innovation and supporting growth in vital industries,” said Nick Ambrosini, President and CEO of Valley Strong Credit Union. “Leading the MAVRK Equity Conduit Fund as the anchor investor—and partnering with respected institutions in their endeavors—underscores our dedication to delivering meaningful impact for our Members, our partners, and the broader community. The opportunity to help MAVRK build this future asset class is an incredible opportunity, and we look forward to scaling this platform for decades to come.”

Performance Trust Capital Partners served as advisor. “It is exciting to see first hand how rapidly the fresh produce market is meeting the private credit investing landscape,” said Paul Limanni, Managing Director and Co-Head of Capital Markets at Performance Trust Capital Partners. “I believe that the MAVRK teams deep expertise in the entire produce vertical will allow institutional investors the ability to pursue meaningful returns at scale with thoughtful risk management.”

About MAVRK Capital, Inc.

MAVRK understands first-hand the challenges farmers face when attempting to access the capital they need to grow their crops and manage cash flow while investing for future growth. That’s why we’re committed to developing flexible finance solutions that provide growers with an affordable option to maintain liquidity while improving margins, reducing and distributing risk and helping to deliver high-quality fresh produce to the world’s leading retailers.

Contact: David Higdon, +16613431840, [email protected]

SOURCE MAVRK Capital, Inc.

Company to receive $100 million in connection with the Exchange Offer on August 8, 2025 and an additional $200 million subject to certain conditions, completing its previously announced financing package of $600 million

Holders of approximately 98% of the aggregate principal amount of the outstanding Old Notes have already tendered in the Exchange Offer and delivered their consents to the proposed amendments

NEW YORK, Aug. 4, 2025 — Saks Global Enterprises LLC (“Saks Global” or the “Company”) today announced the early tender results of the previously announced offer to exchange (the “Exchange Offer”) by Saks Global and SGUS LLC, a Delaware limited liability company and wholly owned subsidiary of Saks Global (“SGUS,” and together with Saks Global, the “Issuers”) any and all of Saks Global’s 11.000% Senior Secured Notes due 2029 (the “Old Notes”) for a combination of certain securities as set forth in, and subject to the terms and conditions of, the offering memorandum and consent solicitation statement dated as of July 21, 2025 (as supplemented or otherwise modified from time to time, the “Offering Memorandum”).

As of 5:00 p.m., New York City time, on August 1, 2025 (the “Early Exchange Time”), the Issuers had received from Eligible Holders (as defined herein) valid and unrevoked tenders and related consents representing approximately 98% of the aggregate principal amount of Old Notes outstanding. At such time, the right to withdraw tenders of Old Notes and related consents expired, and so Old Notes tendered for exchange may not be validly withdrawn and consents may no longer be revoked, unless required by applicable law, or the Issuers determine in the future in their sole discretion to permit withdrawal and revocation rights. Subject to the terms and conditions set forth in the Offering Memorandum, as previously announced, settlement of the Exchange Offer with respect to tenders received as of the Early Exchange Time is expected to occur on August 8, 2025 (the “Early Settlement Date”). The exchange securities are expected to be delivered on the applicable settlement date through the book-entry facilities of DTC.

In connection with the Exchange Offer, on the Early Settlement Date, the Issuers will receive an aggregate of $100 million in gross proceeds from the sale of SPV Notes (as defined in the Offering Memorandum) and will have an additional $200 million in gross proceeds deposited in an escrow account subject to release upon certain conditions. This completes the funding of Saks Global’s previously announced up to $600 million in financing commitments. Saks Global expects to capture approximately $100 million of discount upon issuance of the exchange notes and cancellation of the Old Notes validly tendered.

Marc Metrick, CEO, Saks Global Operating Group, said, “This is an exciting milestone for Saks Global, and we are grateful for the ongoing support of our bondholders. With this incremental liquidity, we can now look forward to strengthening our brand partnerships, as well as improving inventory flow to meet customer demand and prepare for the holiday season. Simultaneously, we are continuing to execute on the already successful integration of the legacy Saks Global and Neiman Marcus Group businesses to reduce costs and drive efficiency. Together, these efforts are positioning us to create growth opportunities for our partners, drive long-term value for our stakeholders and further enhance our experience to better meet the evolving needs of our customers.”

Each of the Exchange Offer and the concurrent consent solicitation (the “Consent Solicitation“) will expire at 5:00 p.m., New York City time, on August 18, 2025, unless extended or terminated earlier (the “Expiration Time“). Subject to the tender acceptable procedures described in the Offering Memorandum, Eligible Holders who validly tender Old Notes after the Early Exchange Time and before the Expiration Time will receive the Late Exchange Consideration, as further described in the Offering Memorandum. Settlement of the Exchange Offer with respect to tenders received after the Early Exchange Time but by the Expiration Time, is expected to occur on August 20, 2025.

Each participating Eligible Holder must tender all of the Old Notes it holds. Partial tenders of Old Notes will not be accepted. No consideration will be paid for Consents in the Consent Solicitation.

The consummation of the Exchange Offer, the Consent Solicitation and the New SPV Notes Issuance (as defined in the Offering Memorandum) are subject to and conditioned upon the satisfaction or waiver by the Issuers of the Requisite Consents Condition and the General Conditions (each as defined in the Offering Memorandum).

The Exchange Offer and Consent Solicitation and offer to participate in the New SPV Notes Issuance are being made, and the SPV Notes and Saks Exchange Notes (each as defined in the Offering Memorandum) are only being offered and issued, to holders of Old Notes that are (a) reasonably believed to be “qualified institutional buyers” as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act“) or (b) persons that are outside of the United States other than “U.S. persons” as defined in Rule 902 under the Securities Act in offshore transactions in compliance with Regulation S under the Securities Act (such holders, the “Eligible Holders“). Only Eligible Holders are authorized to receive or review the Offering Memorandum or to participate in the Exchange Offer and Consent Solicitation.

None of the SPV Notes, the Saks Exchange Notes or the offering thereof have been or will be registered with the Securities and Exchange Commission under the Securities Act, or the securities laws of any other jurisdiction. The SPV Notes and the Saks Exchange Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

Eligible Holders are urged to carefully read the entire Offering Memorandum, including the information presented under the captions of “Forward-Looking Statements” and “Risk Factors” before making any decision with respect to the New SPV Notes Issuance, the Exchange Offer or the Consent Solicitation. None of the Issuers, any subsidiaries of Saks Global, the Exchange Agent (as defined herein), the applicable trustees and collateral agents under the indentures governing the Old Notes, SPV Notes or the Saks Exchange Notes, as applicable, or any of their respective affiliates, makes any recommendation as to whether the Eligible Holders should tender their Old Notes pursuant to the Exchange Offer or deliver consents pursuant to the Consent Solicitation. Each Eligible Holder must make its own decision as to whether to participate in the New SPV Notes Issuance and whether to tender its Old Notes and to deliver Consents.

Epiq Corporate Restructuring, LLC has been appointed as the exchange agent (in such capacity, the “Exchange Agent“) and the information agent (in such capacity, the “Information Agent“) for the Exchange Offer and Consent Solicitation. Questions concerning the Exchange Offer and Consent Solicitation may be directed to the Information Agent, in accordance with the contact details shown on the back cover of the Offering Memorandum.

About Saks Global

Saks Global is the largest multi-brand luxury retailer in the world, comprising Saks Fifth Avenue, Neiman Marcus, Bergdorf Goodman, Saks OFF 5TH, Last Call and Horchow. Its retail portfolio includes 70 full-line luxury locations, additional off-price locations and five distinct e-commerce experiences. With talented colleagues focused on delivering on our strategic vision, The Art of You, Saks Global is redefining luxury shopping by offering each customer a personalized experience that is unmistakably their own. By leveraging the most comprehensive luxury customer data platform in North America, cutting-edge technology, and strong partnerships with the world’s most esteemed brands, Saks Global is shaping the future of luxury retail.

Saks Global Properties & Investments includes Saks Fifth Avenue and Neiman Marcus flagship properties and represents nearly 13 million square feet of prime U.S. real estate holdings and investments in luxury markets.

For more information, follow Saks Global on LinkedIn.

No Offer or Solicitation

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the New SPV Notes Issuance, the Exchange Offer, the Consent Solicitation or the Transactions (as defined in the Offering Memorandum) or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this communication is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.

Forward-Looking Statements

Certain statements made herein are forward-looking within the meaning of applicable securities laws, including the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments. Often, but not always, forward-looking statements can be identified by the forward-looking terminology such as the words “may,” “will,” “expect,” “believe,” “estimate,” “plan,” “could,” “should,” “would,” “anticipate,” “foresee,” “continue,” “intends,” “trends,” “indications,” “anticipates,” “predicts,” “likely” or “potential” or the negative or other variations of these words or other comparable words or phrases.

Forward-looking statements are based on current estimates and assumptions made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that it believes are appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct.

Many factors could cause our actual results, level of activity, performance, achievements, future events or developments to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors:

• the Company’s ability to consummate the Exchange Offer and Consent Solicitation;
• the possibility that the anticipated synergies and other benefits from the recent acquisition will not be realized (partially or at all), or will not be realized within the anticipated time periods;
• the Company’s ability to successfully manage inventory levels;
• increased or new competition;
• changing consumer preferences, demand and fashion trends;
• brand image and reputational risks;
• customer concentration;
• success of the Company’s marketing and advertising programs;
• changes in spending of consumers and lower demand, including as a result of macroeconomic factors such as tariffs and inflation;
• seasonality of business;
• damage to brands and dependence on vendors;
• the Company’s ability to execute retail strategies;
• the possibility that the anticipated benefits of the Company’s partnerships with third parties will not be realized within anticipated time periods;
• reduced flexibility due to restrictive debt covenants;
• future availability of financing and limitations related to changes in the Company’s credit ratings;
• loss of or disruption in centralized distribution centers;
• civil unrest;
• extreme or unseasonable weather conditions or natural disasters;
• international operational risks, including tariffs and political risks;
• fluctuations in the U.S. dollar and other foreign currencies;
• supply disruptions;
• increase in raw material costs;
• insolvency risk of parties with whom the Company does business or their unwillingness to perform their obligations;
• risks related to privacy issues and cyber and other security breaches;
• the Company’s ability to upgrade, maintain and secure our information systems to support the Company’s needs and protect against cybersecurity threats;
• loss of intellectual property rights;
• the Company’s ability to make successful acquisitions, investments, expansions and divestitures;
• ability to maintain adequate financial and management processes and controls;
• the Company’s ability to attract and retain quality employees;
• risks related to labor costs and other challenges from a large workforce, including a deterioration in labor relations;
• the Company’s pension plan funding requirements;
• limits on insurance policies;
• exposure to changes in the real estate market;
• exposure to potential environmental liabilities relating to owned and leased real property;
• loss of flexibility with respect to properties in the real estate joint ventures;
• ability to realize the expected benefits from the real estate joint ventures or to effect a future monetization transaction with each of the real estate joint ventures;
• liabilities associated with lease guarantees and with third parties who have assumed leases from the Company;
• risks related to regulatory liability;
• inability to comply with laws and regulations that impact the Company’s business, which could lead to litigation or regulatory actions against the Company;
• tariffs, duties, border adjustment taxes, trade restrictions, sanctions, quotas and voluntary export restrictions on imposed merchandise;
• non-compliance with changing privacy regulatory environment;
• risks of product liability claims and product recalls;
• risks related to tax matters;
• changes in accounting standards and other risks inherent in the Company’s business and/or factors beyond the Company’s control which could have a material adverse effect on the Company;
• ability to manage indebtedness obligations and cash flow;
• the Company’s ability to obtain additional financing on commercially reasonable terms or at all; and
• risks related to increasing indebtedness and other contractual obligations with the Company’s strategic partnerships.

These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully.

The purpose of the forward-looking statements is to provide the reader with a description of management’s current expectations regarding the Company’s financial performance and may not be appropriate for other purposes; readers should not place undue reliance on forward-looking statements made herein. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Contacts

Copies of all the documents relating to the Exchange Offer and Consent Solicitation may be obtained from the Exchange Agent, subject to confirmation of eligibility through the submission of an eligibility letter, available at https://epiqworkflow.com/cases/SAKSEligibility. Alternatively, you may request the eligibility letter via email to [email protected] (please reference “Saks Global” in the subject line).

SOURCE Saks Global

•     Cash runway extended into the second half of 2026

•     Average sales price per share was over 10% higher than the June 2025 public offering price

SHELTON, Conn., Aug. 4, 2025 — Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that in July 2025 the Company added $6.6 million in gross proceeds ($6.3 million net) by selling 19,868,658 shares of its common stock via its At-the-Market offering (the “ATM”) at an average price of $0.3323 per share. Following such sales of common stock pursuant to the ATM, the Company has 46,035,081 shares of common stock issued and outstanding as of July 31, 2025.

“We were able to take advantage of strong liquidity and favorable prices in our stock last month. The proceeds from these ATM sales strengthen our balance sheet considerably and allow us to continue to advance the clinical trials into the second half of 2026,” said Lewis H. Bender, President and CEO of Intensity. “We are also pleased to announce that the average price per share for these ATM sales was more than 10% higher than our recently completed June 2025 public offering, and the costs to raise this incremental capital were much lower. We will continue to be selective and strategic in the deployment of the remainder of the ATM.”

About At the Market Transactions

“At-the-Market” (ATM) offerings, also known as “ATM” programs, refer to a method where a public company sells its newly issued shares directly into the existing trading market at the prevailing market price, rather than through a traditional underwritten offering. This approach allows companies to raise capital opportunistically and incrementally, as needed, with minimal disruption to the market and typically lower costs.

About INT230-6

INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity’s proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule (“SHAO”) that facilitates the dispersion of potent cytotoxic drugs throughout tumors, allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy.

About Intensity Therapeutics

Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor’s dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity’s clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the “INVINCIBLE-2 Study”) (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the “INVINCIBLE-3 Study”) (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care (“SOC”) with overall survival as an endpoint. Intensity also initiated a Phase 2 study (the “INVINCIBLE-4 Study”) (NCT06358573) in collaboration with the Swiss Cancer Group, formerly the Swiss Group for Clinical Cancer Research, SAKK, as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response (“pCR”) is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company’s expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company’s research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company’s business model, strategic plans for the Company’s business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company’s system; the Company’s competitive position; the Company’s intellectual property position; developments and projections relating to the Company’s competitors and its industry; the Company’s ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market’s requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company’s subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations Contact:
Justin Kulik
[email protected]
CORE IR
(516) 222-2560

Media Contact:
Jules Abraham
CORE IR
[email protected]

SOURCE Intensity Therapeutics Inc.

TUCSON, Ariz., Aug. 4, 2025 — In a U.S. market where fewer than 2% of EMS agencies have implemented prehospital blood programs—and over 70% of those rely on Delta Development Team (DDT) systems—DDT is emerging as the clear leader in a rapidly expanding space. Today, the company announced the successful close of its Series A3 funding round, marking a major milestone in its growth trajectory.

Unlike many startups navigating a tight funding landscape, DDT completed its extended Series A round in just nine months. This momentum is a direct result of its increasing adoption across both civilian and military healthcare sectors, its growing reputation as the gold standard in cold chain technology, and its alignment with evolving protocols that prioritize earlier access to blood in the field.

“This market is transforming fast—and we’re not just keeping pace; we’re driving the shift,” said Montgomery Leija, CEO of Delta Development Team. “From military partnerships to frontline EMS units, our systems are becoming foundational infrastructure for evolving prehospital blood programs.”

The Series A3 round was backed by a mix of strategic capital and non-dilutive funding, including support from the U.S. Air Force’s TACFI (SBIR) program. This funding structure enables DDT to scale quickly while minimizing dilution and operational risk.

Investors

Amongst other investors, this round attracted a consortium of top angel networks known for backing breakthrough healthcare and deep-tech ventures:

• Desert Angels – A cornerstone of the Southwest’s startup scene, Desert Angels has invested over $65 million in more than 165 companies. Their involvement signals strong regional and national belief in Delta’s mission.
• Arizona Tech Investors (ATI) – With a focus on high-growth innovation across Arizona and beyond, ATI’s members bring not only capital but also a deep bench of technical and operational expertise.
• Baylor Angel Network (BAN) – BAN’s unique blend of capital and analytical rigor—powered in part by its student analyst program—adds another layer of strategic insight to Delta’s investor base.
• Pasadena Angels – A force in Southern California’s innovation ecosystem, the Pasadena Angels contribute early-stage funding and mentorship, backed by a network of seasoned executives and entrepreneurs.
• Central Texas Angel Network (CTAN) – Among the most active angel groups in the country, CTAN brings deep experience in scaling early-stage ventures and unlocking growth in complex markets.

About Delta Development Team (DDT)
Delta Development Team is redefining emergency medical care through rugged, field-ready refrigeration, monitoring, and logistics systems. Its mission is to ensure frontline responders have the tools they need to deliver lifesaving blood and biologics when and where they’re needed most.

To learn more, visit deltadevteam.com or contact [email protected].

SOURCE Delta Development Team

SEOUL, South Korea and PALO ALTO, Calif., Aug. 4, 2025 — PhnyX Lab, a pioneering GenAI startup transforming how life science companies operate, announced the successful close of a $4 million seed round through a Simple Agreement for Future Equity (SAFE). The round was led by SK Networks, with participation from several prominent angel investors—including Aidan Gomez, co-founder and CEO of Cohere, and Illia Polosukhin, co-founder of NEAR Protocol—both of whom are original co-authors of “Attention Is All You Need,” the paradigm-shifting work that ushered in the transformer era and laid the foundation for today’s generative AI models, including ChatGPT. Their involvement follows extensive discussions with both Sung-hwan Choi, Executive Advisor to PhnyX Lab and COO of SK Networks, and Min-seok Bae, CEO of PhnyX Lab—reflecting a shared conviction in the transformative role of AI.

“This funding marks an important milestone that reflects PhnyX Lab’s potential to fundamentally transform how life science companies work,” said Min-seok Bae, CEO of PhnyX Lab. “Our mission goes beyond improving efficiency—we’re reimagining the way critical work gets done, helping organizations accelerate not only drug discovery but also approval and delivery. The early success of our Cheiron platform and its rapid adoption by leading pharmaceutical companies has proven the real-world impact of our technology. With this funding, we’re positioned to scale our team, deepen our product capabilities, and forge global partnerships that push the boundaries of what’s possible in life sciences.”

PhnyX Lab’s flagship platform, Cheiron, launched in December 2024, is already gaining strong traction across industry with over 60 companies, including all of Korea’s top 10 pharmaceutical companies by revenue, using Cheiron to streamline complex workflows such as research paper and clinical trial searches.

Building on this momentum, PhnyX Lab is now expanding Cheiron into a broader product suite. In June, the company entered strategic partnerships with SK Biopharmaceuticals and Samil Pharmaceutical to support the development of Cheiron Write—a new offering under the Cheiron brand designed to automate medical writing. Cheiron Write aims to compress documentation workflows that traditionally take months into just weeks or even hours. This expansion marks a pivotal step toward transforming manual, fragmented pharmaceutical processes into intelligent, integrated workflows—bringing the company closer to its vision of fundamentally reengineering how life sciences work.

SOURCE PhnyX Lab LLC

NEW YORK, Aug. 4, 2025 — OrbiMed, a leading global healthcare investment firm, today announced it has raised $1.86 billion in commitments for OrbiMed Royalty and Credit Opportunities Fund V.

Consistent with its predecessors, Fund V will provide tailored investment solutions to growth-oriented healthcare companies, with a focus on non-dilutive credit and royalty-based financing. OrbiMed expects to partner with healthcare companies across many sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.

“Equity markets have been challenging in recent years for biotech and life sciences companies,” said OrbiMed General Partner Matthew Rizzo. “Our flexible, non-dilutive capital solutions can help our portfolio companies to grow and thrive despite these volatile market conditions. The OrbiMed platform is uniquely positioned to fund healthcare innovation and growth on a global basis.”

Investors in this new fund include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. 

“Over 90% of Fund V’s committed capital is from existing, long-standing firm relationships,” said OrbiMed Managing Partner Carter Neild. “We are grateful for this support, and will endeavor to deliver exceptional results to our partners.”

About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 145 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets. For more information, please visit www.orbimed.com or follow us on X @OrbiMed.

SOURCE OrbiMed

Lam Capital Joins Funding Round Alongside Foxconn, Pegatron, and Wistron

TAIPEI, Aug. 1, 2025 — Zettabyte, a fast-growing innovator in AI data center infrastructure software, today jointly announced a new strategic investment by Lam Capital, the corporate venture arm of Lam Research Corp., a global supplier of innovative wafer fabrication equipment and services for the semiconductor industry. The funding round also included participation from Wistron, Foxconn and Pegatron.

Zettabyte is transforming the AI compute landscape with its turnkey GPU cloud infrastructure as a service (IaaS) to enable next-generation AI data centers. The company’s proprietary Zware platform unifies the entire AI infrastructure software stack—from networking to full cluster management. Zware advanced liquid cooling enables a sovereign systems architecture with a focus on cybersecurity, efficiency, and scalability.

Lam Capital’s participation in the round alongside other prominent investors underscores the increasing importance of AI infrastructure as demand for GPU computing continues to outpace supply in the generative AI era. Zettabyte’s vertically integrated software-hardware model is purpose built to address this supply-demand gap, optimizing every layer of AI compute environments.

“Zettabyte operates at the intersection of two megatrends: AI and infrastructure,” said Kevin Chen, managing director at Lam Capital. “This investment highlights the importance of supporting the advancement of next-generation AI data center infrastructure solutions to enable the next wave of innovation across the semiconductor ecosystem.”

The funding round will support Zettabyte in its global expansion efforts and help accelerate the development of Zsuite. Built for end-to-end optimizations and IaaS, Zsuite is designed to significantly reduce total cost of ownership for enterprise and public-sector customers.

“We are honored to welcome Lam Capital as a strategic investor,” said Kenneth Tai, Chairman of Zettabyte. “Their support validates our mission to reimagine AI infrastructure from the ground up—merging performance, efficiency, and sovereignty in a unified platform.”

About Zettabyte
Zettabyte is a global leader in AI data center infrastructure and full-stack GPU software. Its flagship product, Zware, delivers optimized AI computing through custom hardware, advanced cooling, and software-defined orchestration.

SOURCE Zettabyte

 Comp AI Raises $2.6M in Pre-Seed Funding to Revolutionize Enterprise Compliance with AI-Powered Automation  

SAN FRANCISCO, Aug. 1, 2025 — Comp AI, an emerging player in the compliance automation space, today announced it has secured $2.6 million in pre-seed funding to accelerate its mission of transforming how companies achieve compliance with critical frameworks like SOC 2 and HIPAA. The funding round was co-led by OSS Capital and Grand Ventures, both bringing specialized expertise in backing innovative technology companies. OSS Capital, known for investing in open-source challengers including ProjectDiscovery, Plane, and Cal.com, joins Grand Ventures, which has a strong track record supporting developer and infrastructure platforms such as Astronomer, Payload, and Tembo. The round also includes participation from notable angel investors David Cramer, founder of Sentry, and Ben Tossell of Ben’s Bites.

Addressing a Broken Industry
Compliance frameworks like SOC 2, HIPAA, and ISO 27001 have become essential for securing enterprise contracts, but the traditional path to achieving certification remains manual, expensive, and time-consuming. Comp AI is positioning itself as a disruptive alternative by combining open-source collaboration with advanced agentic AI automation. Since emerging from stealth in April 2025, the company reports impressive early traction. Comp AI claims its first batch of customers has collectively saved over 2,500 hours on manual compliance work. The startup has also participated in Vercel’s Spring ’25 OSS initiative and attracted more than 3,500 companies to its pre-launch testing program. The founding team consists of experienced Silicon Valley entrepreneurs Mariano Fuentes, Lewis Carhart, and Claudio Fuentes, who bring firsthand experience with the compliance challenges facing startups. Having navigated SOC 2 compliance at their previous ventures, the trio identified significant inefficiencies in the current market landscape.

Challenging Established Players
Comp AI is directly challenging established compliance platforms, which the company characterizes as costly and labor-intensive solutions that still require founders to spend weeks on manual compliance management. The startup claims its AI-powered approach can automate up to 90% of the compliance process, resulting in what it describes as “instant product-market fit” and monthly growth exceeding 89%.

Investment and Growth Plans
The new funding will support Comp AI’s expansion across multiple fronts over the next three months:

• Open-source platform expansion: Enabling security professionals and auditors to contribute control templates, framework mappings, and automation tools
• AI Agent Studio launch: Moving from beta to general availability, this tool allows customers to deploy automated agents for evidence collection, risk assessments, and vendor onboarding

Industry Recognition
The investment has drawn enthusiastic endorsements from both lead investors.”We have been blown away by Comp AI’s speed of execution and customer obsession. GRC has long been overdue for open source disruption, and Comp AI is delivering that in spades,” said Joseph Jacks, Founder of OSS Capital. Nathan Owen, General Partner at Grand Ventures, added: “GRC – specifically compliance (SOC 2, ISO 27001, GDPR, etc.) – has needed bold innovation for years, and Comp AI is leading the charge. Their platform isn’t an incremental improvement – it’s a complete reinvention.”

Looking Forward
According to the team, as Comp AI continues scaling its operations, the company is actively recruiting new team members. The funding round positions Comp AI to capitalize on the growing demand for streamlined compliance solutions as more companies seek to accelerate their path to enterprise readiness in an increasingly regulated business environment.

About Comp AI
Comp AI is a San Francisco-based startup founded in 2025 that’s revolutionizing how companies approach compliance certification. The company provides an AI-powered trust management platform that automates compliance for major frameworks, including SOC 2, HIPAA, GDPR, ISO 27001, and 25+ other regulatory standards.

Mission: To help 100,000 companies achieve SOC 2, ISO 27001, and GDPR compliance by 2032, making enterprise-grade security accessible to companies of all sizes without the traditional $25K+ annual costs and complexity. Comp AI is positioned as “the Vercel of compliance” – offering a developer-friendly, modern alternative to legacy compliance platforms that are often slow, expensive, and built primarily for large enterprises.

Contact:-

CEO, Founder
Lewis Carhart
Bubba AI, Inc.
[email protected]     

Photo: https://mma.prnewswire.com/media/2742766/Comp_AI_Team.jpg
Photo: https://mma.prnewswire.com/media/2742767/Comp_AI.jpg

SOURCE Comp AI

Maverick Capital Led the Oversubscribed Round with StepStone Group Joining as a New Investor

SAN JOSE, Calif., Aug. 1, 2025 — SiMa.ai, a pioneer in delivering purpose-built hardware and software solutions for Physical AI, today announced it has raised $85 million in an oversubscribed round, bringing total capital raised to $355 million. The latest round was led by Maverick Capital, with continued participation from existing investors and new investor StepStone Group.

This funding will fuel SiMa.ai’s global expansion and accelerate the scale-up of its Physical AI platform, including increased investment in software innovation, go-to-market operations, customer success, and strengthening the automotive roadmap.

“This new funding further validates our leadership in the Physical AI space and the growing demand for Physical AI solutions that deliver best-in-class performance per watt with industry-leading ease of use,” said Krishna Rangasayee, Founder and CEO at SiMa.ai. “With strong support from new and existing investors, we’re scaling quickly to extend our competitive lead and meet global customer demand across robotics, automotive, industrial automation, aerospace & defense, smart vision, and healthcare.”

SiMa.ai delivers the industry’s leading full-stack Physical AI platform with SiMa.ai ONE—an integrated, power-efficient solution combining purpose-built silicon and a software-centric approach to simplify deployment and maximize performance. The platform features Modalix, its second-gen multimodal MLSoC now shipping, and Palette, a comprehensive software suite with both SDK and Edgematic, a no-code visual development tool. Supporting all major ML frameworks—including vision, transformers, and generative AI—on a unified architecture, SiMa.ai enables fast, efficient AI adoption across real-world use cases across customers in robotics, automotive, industrial automation, aerospace & defense, smart vision, and healthcare.

“SiMa.ai is redefining what’s possible at the edge by combining world-class silicon with a uniquely software-centric approach to Physical AI. Their ability to deliver high-performance, low-power solutions with frictionless deployment positions them to lead in a market that’s scaling fast. We’re thrilled to support SiMa.ai as they accelerate their growth and continue to deliver transformative value across industries,” said Andrew Homan, Managing Partner at Maverick Capital.

“As generative AI transforms the data center landscape, we see immense opportunity in the next phase of innovation—AI at the edge,” said John Avirett, Partner at StepStone Group. “SiMa.ai’s full-stack solution, technical depth, and growing customer adoption make it a clear leader in this space. We’re excited to join the company’s journey and support its mission to drive efficient, scalable AI across real-world edge applications.”

As demand surges for AI at the edge—where power efficiency, performance, and simplicity are paramount—SiMa.ai continues to lead with a differentiated approach. By addressing the full system problem on a single chip and pairing it with a software stack optimized for developer experience, SiMa.ai is poised to lead the next wave of Physical AI innovation.

About SiMa.ai
SiMa.ai is a pioneer in Physical AI computing, developing innovative platforms that enable intelligent applications at the edge. The company’s Modalix platform delivers exceptional AI performance with industry-leading energy efficiency, making advanced AI capabilities accessible across diverse industries and applications such as robotics, automotive, industrial automation, aerospace & defence, smart vision and healthcare. Founded by seasoned technology veterans, SiMa.ai is headquartered in San Jose, California. For more information, visit www.sima.ai.

SOURCE SiMa.ai